StreetInsider.com News Articles

PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026

Tue, 27 Oct 2026 16:15:00 -0500

DELRAY BEACH, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the second quarter fiscal year ended September 30, 2026, on Tuesday, November 10, 2026 after market close. The Company will host a conference call and webcast to review these results at 4:30pm Eastern Time on the same day.

Date: Tuesday, November 10, 2026
Time: 4:30pm Eastern Time (1:30pm Pacific Time)
U.S. dial-in number: 877-407-0789
International number: 201-689-8562
Webcast: 2Q Earnings Webcast

A telephonic replay of the conference

PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026

Tue, 27 Oct 2026 16:15:00 -0500

Date: Tuesday, November 10, 2026
Time: 4:30pm Eastern Time (1:30pm Pacific Time)
U.S. dial-in number: 877-407-0789
International number: 201-689-8562
Webcast: 2Q Earnings Webcast

A telephonic replay of the conference

PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:05:00 -0500

DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment.

On September 28, 2026, PetMeds granted Jeff Willard, Chief Executive Officer and President, 250,000 shares of restricted common stock and 250,000 performance share units (“PSUs”), and on October 1, 2026, PetMeds granted Andrew Parry, Chief Technology Officer, 100,000 shares of restricted common stock.

The awards were granted pursuant to

PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:05:00 -0500

The awards were granted pursuant to

Form 4 PETMED EXPRESS INC For: Sep 28 Filed by: Willard Jeffrey Allen

Tue, 29 Sep 2026 16:36:00 -0500

si-local-file:///var/storage/secattach/20260929/27123007.html

Form 3 PETMED EXPRESS INC For: Sep 28 Filed by: Willard Jeffrey Allen

Tue, 29 Sep 2026 16:35:00 -0500

si-local-file:///var/storage/secattach/20260929/27122998.html

Form S-8 PETMED EXPRESS INC

Mon, 28 Sep 2026 16:41:00 -0500

si-local-file:///var/storage/secattach/20260928/27115156.html

Form S-8 PETMED EXPRESS INC

Mon, 28 Sep 2026 16:36:00 -0500

si-local-file:///var/storage/secattach/20260928/27115074.html

Form 8-K PETMED EXPRESS INC For: Sep 27

Mon, 28 Sep 2026 16:27:00 -0500

si-local-file:///var/storage/secattach/20260928/27114883.html

PetMed Express (PETS) PT Lowered to $1.40 at Morgan Stanley

Fri, 25 Sep 2026 08:27:57 -0500

Morgan Stanley analyst Erin Wright lowered the price target on PetMed Express (NASDAQ: PETS) to $1.40 (from $2.15) while maintaining a Underweight rating.

Form 4 PETMED EXPRESS INC For: Sep 17 Filed by: Elkeles Tamar

Mon, 21 Sep 2026 08:59:00 -0500

si-local-file:///var/storage/secattach/20260921/27083534.html

Form 3 PETMED EXPRESS INC For: Sep 17 Filed by: Elkeles Tamar

Mon, 21 Sep 2026 08:55:00 -0500

si-local-file:///var/storage/secattach/20260921/27083524.html

Form 8-K PETMED EXPRESS INC For: Sep 15

Mon, 21 Sep 2026 08:35:00 -0500

si-local-file:///var/storage/secattach/20260921/27083423.html

PetMeds adds Tamar Elkeles to its board as independent director

Mon, 21 Sep 2026 08:31:45 -0500

PetMed Express, Inc. (NASDAQ: PETS), the parent company of PetCareRx, announced the appointment of Tamar Elkeles, PhD, as a new independent director and Chair of the Compensation and Human Capital Committee, effective September 17, 2026.

Dr. Elkeles has more than three decades of experience as an executive, board member, and strategic advisor in the technology, enterprise software, and human capital industries. From 1992 to 2015, she served as Chief Learning & Talent Officer at Qualcomm, where she contributed to the company's growth from $100 million to more than $25 billion in revenue and its workforce expansion from 700 to 35,000 employees.

She

PetMeds adds Tamar Elkeles to its board as independent director

Mon, 21 Sep 2026 08:31:45 -0500

She

PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director

Mon, 21 Sep 2026 08:30:00 -0500

DELRAY BEACH, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Tamar Elkeles, PhD as a new independent director and Chair of the Compensation and Human Capital Committee, effective September 17, 2026.

Dr. Elkeles brings more than three decades of experience as an executive, board member, and strategic advisor across the technology, enterprise software and human capital industries. From 1992 to 2015, she served as Chief Learning & Talent Officer at Qualcomm, where she helped shape the human capital strategy that supported

PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director

Mon, 21 Sep 2026 08:30:00 -0500

Form 8-K PETMED EXPRESS INC For: Sep 17

Thu, 17 Sep 2026 09:09:00 -0500

si-local-file:///var/storage/secattach/20260917/27073702.html

PetMeds names Jeff Willard as CEO, board chair to retire

Thu, 17 Sep 2026 08:30:36 -0500

PetMed Express, Inc. (NASDAQ: PETS), the parent company of PetCareRx, announced the appointment of Jeff Willard as Chief Executive Officer and President, effective September 28, 2026. Willard will also join the company's Board of Directors on that date.

Willard succeeds Leslie C.G. Campbell, who has served as Interim Chief Executive Officer and President since August 2025. Most recently, Willard served as CEO of Stewart-MacDonald, an e-commerce provider of guitar tools and parts. He previously held roles including Chief Growth Officer and Chief Marketing Officer at Casper, President of Healthy Lifestyle Brands, and CEO of Zac Brown Collective. Earlier positions included senior

PetMeds names Jeff Willard as CEO, board chair to retire

Thu, 17 Sep 2026 08:30:36 -0500

PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition

Thu, 17 Sep 2026 08:30:00 -0500

DELRAY BEACH, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of consumer and e-commerce sector veteran, Jeff Willard, as Chief Executive Officer and President, as well as a member of the Board of Directors, effective September 28, 2026. Mr. Willard succeeds Leslie C.G. Campbell, who, in addition to serving as Chair of the Board of PetMeds, has served as Interim Chief Executive Officer and President since August 2025.

Mr. Willard brings more than 25 years of proven leadership experience at leading consumer

PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition

Thu, 17 Sep 2026 08:30:00 -0500

Mr. Willard brings more than 25 years of proven leadership experience at leading consumer

PetMeds names Andrew Parry as chief technology officer

Mon, 14 Sep 2026 16:05:42 -0500

PetMed Express, Inc. (NASDAQ: PETS), which operates under the PetMeds brand and owns PetCareRx, announced the appointment of Andrew Parry as Chief Technology Officer, effective immediately, according to a company press release.

Parry will oversee technology strategy, platform architecture, and engineering across the company's e-commerce, pharmacy, and enterprise systems.

Parry joins PetMeds from The ODP Corporation, where he served as Senior Vice President and Chief Information Officer. In that role, he led technology operations for the company's retail, business solutions, and supply-chain units and executed a multi-year initiative to implement generative AI and workflow automation. He was appointed Chief Information Officer at

PetMeds Appoints Andrew Parry as Chief Technology Officer

Mon, 14 Sep 2026 16:05:00 -0500

DELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Andrew Parry as Chief Technology Officer, effective immediately. Parry will lead the Company's technology strategy, platform architecture and engineering execution across its e-commerce, pharmacy and enterprise systems.

Parry brings more than three decades of technology leadership experience and joins PetMeds from The ODP Corporation, where he most recently served as Senior Vice President and Chief Information Officer, leading technology for the retail, business solutions and supply-chain units. In that

PetMeds Appoints Andrew Parry as Chief Technology Officer

Mon, 14 Sep 2026 16:05:00 -0500